A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety
of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23
ovarian cancer，37 endometrial cancer，26 cervical cancer.